Hubbry Logo
CYP2E1CYP2E1Main
Open search
CYP2E1
Community hub
CYP2E1
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
CYP2E1
CYP2E1
CYP2E1
View on Wikipedia
from Wikipedia
CYP2E1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCYP2E1, CPE1, CYP2E, P450-J, P450C2E, cytochrome P450 family 2 subfamily E member 1
External IDsOMIM: 124040; MGI: 88607; HomoloGene: 68089; GeneCards: CYP2E1; OMA:CYP2E1 - orthologs
EC number1.14.13.n7
Orthologs
SpeciesHumanMouse
Entrez

1571

13106

Ensembl

ENSG00000130649

ENSMUSG00000025479

UniProt

P05181

Q05421

RefSeq (mRNA)

NM_000773

NM_021282

RefSeq (protein)

NP_000764

NP_067257

Location (UCSC)Chr 10: 133.52 – 133.56 MbChr 7: 140.34 – 140.35 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cytochrome P450 2E1 (abbreviated CYP2E1, EC 1.14.13.n7) is a member of the cytochrome P450 mixed-function oxidase system, which is involved in the metabolism of xenobiotics in the body. This class of enzymes is divided up into a number of subcategories, including CYP1, CYP2, and CYP3, which as a group are largely responsible for the breakdown of foreign compounds in mammals.[5]

While CYP2E1 itself carries out a relatively low number of these reactions (~4% of known P450-mediated drug oxidations), it and related enzymes CYP1A2 and CYP3A4 are responsible for the breakdown of many toxic environmental chemicals and carcinogens that enter the body, in addition to basic metabolic reactions such as fatty acid oxidations.[6]

CYP2E1 protein localizes to the endoplasmic reticulum and is induced by ethanol, the diabetic state, and starvation. The enzyme metabolizes both endogenous substrates, such as ethanol, acetone, and acetal, as well as exogenous substrates including benzene, carbon tetrachloride, ethylene glycol, and nitrosamines which are premutagens found in cigarette smoke. Due to its many substrates, this enzyme may be involved in such varied processes as gluconeogenesis, hepatic cirrhosis, diabetes, and cancer.[7]

Function

[edit]

CYP2E1 is a membrane protein expressed in high levels in the liver, where it composes nearly 50% of the total hepatic cytochrome P450 mRNA[8] and 7% of the hepatic cytochrome P450 protein.[9] The liver is therefore where most drugs undergo deactivation by CYP2E1, either directly or by facilitated excretion from the body.

CYP2E1 enzyme metabolizes mostly small, polar molecules, including toxic laboratory chemicals such as dimethylformamide, aniline, and halogenated hydrocarbons (see table below). While these oxidations are often of benefit to the body, certain carcinogens and toxins are bioactivated by CYP2E1, implicating the enzyme in the onset of hepatotoxicity caused by certain classes of drugs (see disease relevance section below).

CYP2E1 also plays a role in several important metabolic reactions, including the conversion of ethanol to acetaldehyde and to acetate in humans,[10] where it works alongside alcohol dehydrogenase and aldehyde dehydrogenase. In the conversion sequence of acetyl-CoA to glucose, CYP2E1 transforms acetone via hydroxyacetone (acetol) into propylene glycol and methylglyoxal, the precursors of pyruvate, acetate and lactate.[11][12][13]

CYP2E1 also carries out the metabolism of endogenous fatty acids such as the ω-1 hydroxylation of fatty acids such as arachidonic acid, involving it in important signaling pathways that may link it to diabetes and obesity.[14] Thus, it acts as a monooxygenase to metabolize arachidonic acid to 19-hydroxyeicosatetraenoic acid (19-HETE) (see 20-Hydroxyeicosatetraenoic acid). However, it also acts as an epoxygenase activity to metabolize docosahexaenoic acid to epoxides, primarily 19R,20S-epoxyeicosapentaenoic acid and 19S,20R-epoxyeicosapentaenoic acid isomers (termed 19,20-EDP) and eicosapentaenoic acid to epoxides, primarily 17R,18S-eicosatetraenoic acid and 17S,18R-eicosatetraenoic acid isomers (termed 17,18-EEQ).[15] 19-HETE is an inhibitor of 20-HETE, a broadly active signaling molecule, e.g. it constricts arterioles, elevates blood pressure, promotes inflammation responses, and stimulates the growth of various types of tumor cells; however the in vivo ability and significance of 19-HETE in inhibiting 20-HETE has not been demonstrated. The EDP (epoxydocosapentaenoic acid) and EEQ (epoxyeicosatetraenoic acid) metabolites have a broad range of activities. In various animal models and in vitro studies on animal and human tissues, they decrease hypertension and pain perception; suppress inflammation; inhibit angiogenesis, endothelial cell migration and endothelial cell proliferation; and inhibit the growth and metastasis of human breast and prostate cancer cell lines.[16][17][18][19] It is suggested that the EDP and EEQ metabolites function in humans as they do in animal models and that, as products of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid, the EDP and EEQ metabolites contribute to many of the beneficial effects attributed to dietary omega-3 fatty acids.[16][19][20] EDP and EEQ metabolites are short-lived, being inactivated within seconds or minutes of formation by epoxide hydrolases, particularly soluble epoxide hydrolase, and therefore act locally. CYP2E1 is not regarded as being a major contributor to forming the cited epoxides[19] but could act locally in certain tissues to do so.

Substrates

[edit]

Following is a table of selected substrates of CYP2E1. Where classes of agents are listed, there may be exceptions within the class.

Selected substrates of CYP2E1
Substrates

Structure

[edit]

CYP2E1 exhibits structural motifs common to other human membrane-bound cytochrome P450 enzymes, and is composed of 12 major α-helices and 4 β-sheets with short intervening helices interspersed between the two.[14] Like other enzymes of this class, the active site of CYP2E1 contains an iron atom bound by a heme center which mediates the electron transfer steps necessary to carry out oxidation of its substrates. The active site of CYP2E1 is the smallest observed in human P450 enzymes, with its small capacity attributed in part to the introduction of an isoleucine at position 115. The side-chain of this residue protrudes out above the heme center, restricting active site volume compared to related enzymes that have less bulky residues at this position.[14] T303, which also protrudes into the active site, is particularly important for substrate positioning above the reactive iron center and is hence highly conserved by many cytochrome P450 enzymes.[14] Its hydroxyl group is well-positioned to donate a hydrogen bond to potential acceptors on the substrate, and its methyl group has also been implicated in the positioning of fatty acids within the active site.[25][26] A number of residues proximal to the active site including L368 help make up a constricted, hydrophobic access channel which may also be important for determining the enzyme's specificity towards small molecules and ω-1 hydroxylation of fatty acids.[14]

Selected residues in the active site of CYP2E1. Created using 3E4E (bound to inhibitor 4-methyl pyrazole).

Regulation

[edit]

Genetic regulation

[edit]

In humans, the CYP2E1 enzyme is encoded by the CYP2E1 gene.[27] The enzyme has been identified in fetal liver, where it is posited to be the predominant ethanol-metabolizing enzyme, and may be connected to ethanol-mediated teratogenesis.[28] In rats, within one day of birth the hepatic CYP2E1 gene is activated transcriptionally.

CYP2E1 expression is easily inducible, and can occur in the presence of a number of its substrates, including ethanol,[22] isoniazid,[22] tobacco,[29] isopropanol,[6] benzene,[6] toluene,[6] and acetone.[6] For ethanol specifically, it seems that there exist two stages of induction, a post-translational mechanism for increased protein stability at low levels of ethanol and an additional transcriptional induction at high levels of ethanol.[30]

Chemical regulation

[edit]

CYP2E1 is inhibited by a variety of small molecules, many of which act competitively. Two such inhibitors, indazole and 4-methylpyrazole, coordinate with the active site's iron atom and were crystallized with recombinant human CYP2E1 in 2008 to give the first true crystal structures of the enzyme.[14] Other inhibitors include diethyldithiocarbamate[21] (in cancer), and disulfiram[22] (in alcoholism).

Disease relevance

[edit]

CYP2E1 is expressed in high levels in the liver, where it works to clear toxins from the body.[8][9] In doing so, CYP2E1 bioactivates a variety of common anesthetics, including paracetamol (acetaminophen), halothane, enflurane, and isoflurane.[6] The oxidation of these molecules by CYP2E1 can produce harmful substances such as trifluoroacetic acid chloride from halothane [31] or NAPQI from paracetamol (acetaminophen) and is a major reason for their observed hepatotoxicity in patients.

CYP2E1 and other cytochrome P450 enzymes can inadvertently produce reactive oxygen species (ROS) in their active site when catalysis is not coordinated correctly, resulting in potential lipid peroxidation as well as protein and DNA oxidation.[14] CYP2E1 is particularly susceptible to this phenomenon compared to other P450 enzymes, suggesting that its expression levels may be important for negative physiological effects observed in a number of disease states.[14]

CYP2E1 expression levels have been correlated with a variety of dietary and physiological factors, such as ethanol consumption,[32] diabetes,[33] fasting,[34] and obesity.[35] It appears that cellular levels of the enzyme may be controlled by the molecular chaperone HSP90, which upon association with CYP2E1 allows for transport to the proteasome and subsequent degradation. Ethanol and other substrates may disrupt this association, leading to the higher expression levels observed in their presence.[36] The increased expression of CYP2E1 accompanying these health conditions may therefore contribute to their pathogenesis by increasing the rate of production of ROS in the body.[14]

According to a 1995 publication by Y Hu et al., a study in rats revealed a 8- to 9-fold elevation of CYP2E1 with fasting alone, compared to a 20-fold increase in enzyme level accompanied by a 16-fold increase in total catalytic capacity in rats who were both fasted and given large quantities of ethanol for 3 consecutive days. Starvation appears to upregulate CYP2E1 mRNA production in liver cells while alcohol seems to stabilize the enzyme itself post-translation and thus protect it from degradation by normal cellular proteolytic processes, giving the two an independent synergistic effect.

Applications

[edit]

Trees have been genetically engineered to overexpress rabbit CYP2E1 enzyme. These transgenic trees have been used to remove pollutants from groundwater, a process known as phytoremediation.[37]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

CYP2E1

View on Grokipedia
from Grokipedia
Cytochrome P450 2E1 (CYP2E1) is a heme-containing belonging to the superfamily of monooxygenases, which catalyzes the oxidation of a wide range of small endogenous and exogenous substrates through the insertion of an oxygen atom into carbon-hydrogen bonds. Primarily expressed in the liver's , with lower levels in tissues such as the , , , and , CYP2E1 plays a critical role in phase I drug metabolism and . It exhibits particularly high activity toward at the omega-1 position and is the principal P450 isoform responsible for ethanol metabolism, converting it to the toxic intermediate , a process shared with and . This enzyme's induction by chronic alcohol consumption leads to elevated production, contributing to and . CYP2E1 also bioactivates numerous procarcinogens and hepatotoxins, including nitrosamines, , , acetaminophen, and volatile anesthetics like , thereby linking it to chemical-induced cancers, drug toxicities, and diseases such as non-alcoholic . Structurally, CYP2E1 features a compact suited for small hydrophobic molecules, with revealing conformational flexibility that accommodates substrates like fatty acids, and its involves NADPH-dependent , often facilitated by b5. Regulation of CYP2E1 expression occurs primarily at the transcriptional level, influenced by factors including , , , and certain drugs, resulting in stabilization of the enzyme protein and increased activity without proportional mRNA elevation. Genetic polymorphisms in the CYP2E1 gene exhibit ethnic variations, affecting susceptibility to toxin-induced pathologies, though environmental factors like diet and body mass also modulate its expression. In the , CYP2E1 contributes to local oxidation and potential neurotoxic effects via formation and oxidative damage.

Genetics

Gene Structure and Location

The CYP2E1 gene is located on the q26.3 band of the long arm of human 10, with genomic coordinates spanning from 133,527,363 to 133,539,123 in the GRCh38.p14 assembly, encompassing approximately 11.8 kb (11,761 bp) of genomic DNA. This positioning places it near the telomeric region of the , contributing to its role in a cluster of genes evolved through duplication events. The gene is organized into 9 exons separated by 8 s. Exon 1 is untranslated and contains part of the , while exons 2 through 9 encode the full-length 493-amino-acid protein; representative exon sizes include exon 1 at about 200 , exons 2-8 ranging from 100 to 300 , and exon 9 at approximately 800 , with intron boundaries adhering to the standard GT-AG splice consensus. This compact architecture facilitates efficient transcription and splicing, characteristic of the CYP2 subfamily genes. The promoter region, located upstream of exon 1, features a typical approximately 30 bp upstream of the transcription start site, which supports basal transcriptional initiation, along with multiple binding sites for the liver-enriched HNF-1 that enhance tissue-specific expression. These elements contribute to the gene's responsiveness to developmental and environmental cues without relying on a TATA-less configuration. CYP2E1 exhibits strong evolutionary conservation across mammals, reflecting its essential role in metabolism; orthologs include Cyp2e1 in the on (coordinates 140,343,652-140,354,900, GRCm39) and in the on , sharing over 80% sequence identity in the coding regions. This conservation underscores the gene's ancient origin within the superfamily, predating mammalian divergence.

Polymorphisms and Variants

The cytochrome P450 2E1 (CYP2E1) gene exhibits several common polymorphisms, primarily in its regulatory regions, which influence enzyme expression and activity. According to the PharmVar database, these are classified into star (*) alleles, such as *1A (wild-type), *5B, and *6. One prominent variant is the DraI polymorphism (rs6413432, T>A in 6), where the A (*6) abolishes a DraI restriction site and is associated with altered . frequencies for this variant show ethnic variation, with the A occurring at approximately 2-8% in Caucasian populations and 25-36% in East Asian populations. Another key polymorphism is the RsaI variant (often referring to the linked rs2031920 and rs3813867 in the 5' flanking region, defining the *5B ), detected by RsaI and restriction enzymes, where the c2 (T at rs2031920, C at rs3813867) correlates with enhanced promoter activity. The c2 frequency is about 7% in Caucasians but rises to 20-28% in Asians. Additionally, a 96-bp insertion/deletion in the 5' flanking region (distinguishing *1D from *1A ) affects gene regulation; the insertion is low at around 2% in Caucasians but 15-23% in Asian populations. These regulatory polymorphisms generally lead to increased CYP2E1 transcription rates and greater inducibility, particularly by , compared to wild-type alleles. For instance, the DraI A and RsaI c2 variants enhance basal expression and responsiveness to inducers, potentially elevating production and metabolic capacity. The 96-bp insertion similarly boosts promoter strength, resulting in higher levels in carriers. In contrast, rare missense variants, such as Arg76His (rs72559710, *2 allele), impair protein stability and reduce overall enzymatic activity, though these occur at very low frequencies (<1% across populations). Recent studies have linked specific CYP2E1 variants to metabolic risks. A 2023 case-control study in Chinese women found the C-1054T polymorphism associated with elevated gestational diabetes mellitus risk under recessive, dominant, and allelic models, with the T allele tied to greater insulin resistance. Additionally, a 2025 investigation in breast cancer patients revealed that CYP2E1 polymorphisms, in combination with CYP2D6 variants, contribute to chemotherapy-induced peripheral neuropathy toxicity, particularly with doxorubicin-based regimens.
Polymorphismrs ID / LocationVariant AlleleFrequency in CaucasiansFrequency in AsiansFunctional Effect
DraIrs6413432 / Intron 6 (T>A)A2-8%25-36%Increased transcription and inducibility by
RsaI (*5B )rs2031920 & rs3813867 / 5' flankingc2 (T & C alleles)~7%20-28%Enhanced promoter activity
96-bp insertion*1D / 5' flankingInsertion~2%15-23%Higher basal and inducible expression
Arg76Hisrs72559710 / Coding (R76H)A (His)<1%<1%Reduced enzyme stability and activity

Expression and Regulation

Tissue Distribution and Induction

CYP2E1 is predominantly expressed in the liver, where it accounts for approximately 15-20% of the total cytochrome P450 protein and a substantial portion of hepatic P450 mRNA. Lower levels of expression are observed in extrahepatic tissues, including the lungs, kidneys, and small intestine, as well as the brain, nasal mucosa, and other sites. This distribution supports its role in both hepatic and systemic metabolism of xenobiotics and endogenous substrates. The expression of CYP2E1 is highly inducible under various physiological and pathological conditions. Chronic ethanol exposure is a potent inducer, increasing CYP2E1 protein and activity by 1.5- to 4-fold in humans through mechanisms involving protein stabilization and some transcriptional upregulation; mRNA levels increase modestly in response to prolonged ethanol consumption. Fasting and starvation similarly elevate CYP2E1 levels, as do conditions such as diabetes, where induction is partly mediated by peroxisome proliferator-activated receptor α (PPARα), and obesity, which enhances expression via insulin resistance and altered lipid metabolism. Developmentally, CYP2E1 expression is low or undetectable in the fetal liver, with levels increasing markedly postnatally and reaching adult patterns within the first few months of life. Sex differences are evident, with higher CYP2E1 expression and activity typically observed in males compared to females. These patterns of distribution and induction highlight CYP2E1's adaptability to environmental and metabolic stressors.

Regulatory Mechanisms

The expression of CYP2E1 is tightly controlled through multiple regulatory layers, ensuring its levels respond appropriately to physiological and environmental cues. At the transcriptional level, the liver-enriched transcription factor binds directly to specific sites in the CYP2E1 promoter, activating basal gene expression in hepatocytes. Members of the CCAAT/enhancer-binding protein (C/EBP) family, particularly C/EBP-β, also interact with promoter elements to modulate transcription, contributing to both constitutive activity and responses to signals like interleukin-4. Ethanol-responsive elements within the promoter facilitate induction, partly through relief of inhibitory mechanisms that maintain low basal levels under normal conditions. Post-transcriptional regulation fine-tunes mRNA abundance and translation efficiency. Ethanol exposure stabilizes mRNA, increasing its half-life and enhancing protein synthesis, though this effect is secondary to protein-level changes. Specific untranslated regions in the mRNA, including a 16-nucleotide sequence, mediate this stabilization and control translational efficiency, as demonstrated in insulin-responsive models that share mechanistic overlap with ethanol induction. Post-translational modifications and protein stability represent a primary control point for CYP2E1 activity. Phosphorylation by protein kinase A (PKA) at key serine residues reduces enzymatic activity and alters substrate specificity, providing a rapid mechanism to downregulate function during signaling events like cAMP elevation. Substrate binding, including by ethanol, stabilizes the protein by inhibiting ubiquitination and proteasomal degradation, extending the half-life from approximately 7 hours in untreated states to 37-38 hours upon induction. This stabilization reduces the formation of high-molecular-weight ubiquitin conjugates, protecting CYP2E1 from rapid turnover. A positive feedback loop amplifies CYP2E1 expression through reactive oxygen species (ROS) generated during its catalytic activity. Elevated ROS activates signaling pathways, including PKC/JNK/SP1, which further induce CYP2E1 transcription, perpetuating oxidative stress in conditions like chronic ethanol exposure. This autoregulatory mechanism underscores CYP2E1's role in amplifying responses to xenobiotics.

Structure

Overall Architecture

CYP2E1 is a monomeric protein consisting of 493 amino acids with a calculated molecular weight of approximately 57 kDa. As an integral membrane protein, it is embedded in the endoplasmic reticulum (ER) membrane primarily through an N-terminal transmembrane helix spanning residues 1–29, which anchors the enzyme in the lipid bilayer and positions the catalytic domain toward the cytosol. This helical segment facilitates proper orientation for interaction with redox partners like cytochrome P450 reductase. The core architecture of CYP2E1 follows the canonical cytochrome P450 fold, characterized by 12 major α-helices labeled A through L and four antiparallel β-sheets (β1–β4). These elements form a globular domain that houses the heme prosthetic group, a protoporphyrin IX with an iron atom at its center, which is axially coordinated on the proximal side by the thiolate of Cys488. The heme is nestled between helices I and L, with the distal face exposed to the active site cavity, enabling oxygen activation during catalysis. High-resolution crystal structures of human , determined in 2008, reveal a compact, solvent-exposed surface dominated by a positively charged "bowl" on the proximal face for reductase binding, alongside a narrow, hydrophobic channel leading to the buried active site. These structures (PDB: 3E4E at 2.6 Å resolution with 4-methylpyrazole; PDB: 3E6I at 2.2 Å with indazole) highlight the enzyme's overall rigidity, with the substrate access channel measuring about 12 Å in length and constricted by residues from helices F, G, and I, accommodating small hydrophobic molecules. Subsequent structures, such as PDB: 3LC4 (2010), confirm this architecture while showing minor conformational adjustments for larger ligands. Later structures, such as PDB 3T3Z (2011, 2.35 Å with pilocarpine), further confirm this compact architecture with subtle adjustments for diverse ligands. In solution, CYP2E1 behaves as a monomer, but in microsomal membranes, it exhibits oligomerization tendencies, including dimer and higher-order complex formation that may modulate enzymatic activity through allosteric effects or enhanced stability. These interactions, observed via luminescence resonance energy transfer, suggest physiological relevance in the crowded ER environment.

Active Site and Substrate Binding

The active site of CYP2E1 is a compact, hydrophobic cavity positioned directly above the heme prosthetic group, with a volume of approximately 190 ų in inhibitor-bound structures, making it the smallest among characterized human cytochrome P450 enzymes. This limited space restricts access primarily to low-molecular-weight substrates, such as ethanol and acetaminophen. Key residues lining the active site include Thr303, which facilitates hydrogen bonding with substrate polar groups; Ile115, contributing to hydrophobic interactions and gating at the channel entrance; and Val364, which constricts the binding pocket through van der Waals contacts. Additional hydrophobic residues, such as Phe106, Phe116, Phe207, Phe298, Ala299, and Leu368, form a tight enclosure that enforces precise substrate orientation. Substrates access the active site via a narrow channel originating from the protein surface, bordered by the B-C loop, F helix, and β-sheets 1 and 4, which favors entry of small, hydrophilic species while excluding larger compounds. The channel is partially gated by the bulky side chain of Ile115, creating a hydrophobic barrier that modulates substrate ingress and egress. Val364 further narrows the pathway near the heme, ensuring substrates are positioned optimally for catalysis. In binding modes, ethanol coordinates primarily through its hydroxyl group forming a hydrogen bond with the side chain of Thr303, stabilizing the molecule in a productive orientation for oxidation. For acetaminophen, the aromatic ring engages in π-π stacking and hydrophobic interactions with phenylalanine residues like Phe298 and Phe478, anchoring it within the compact pocket. These interactions highlight CYP2E1's selectivity for planar, aromatic small molecules alongside aliphatic ones. Upon substrate binding, subtle conformational adjustments occur, including a minor shift in helix I (approximately 0.4 Å in modeled complexes), which repositions residues near the heme to facilitate oxygen activation without major structural rearrangements. This dynamic response, observed in the context of the enzyme's overall α-helical fold, underscores the active site's adaptability while maintaining its restrictive geometry.

Function

Catalytic Mechanism

CYP2E1 functions as a monooxygenase enzyme, catalyzing the oxidation of substrates (RH) by incorporating one oxygen atom from molecular oxygen into the substrate to form a hydroxylated product (ROH), while the second oxygen atom is reduced to water. The overall reaction is RH + O₂ + NADPH + H⁺ → ROH + NADP⁺ + H₂O, classified under EC 1.14.14.1. This process requires the transfer of two electrons from NADPH via the accessory protein cytochrome P450 reductase (CPR), which contains FAD and FMN cofactors to mediate electron delivery. The catalytic cycle of CYP2E1 follows the canonical cytochrome P450 mechanism, initiating with the resting enzyme in a low-spin ferric (Fe³⁺) heme state. Substrate binding induces a conformational change that shifts the heme iron to a high-spin Fe³⁺ state, lowering the redox potential and facilitating the first electron transfer from CPR to produce the ferrous (Fe²⁺) form. Oxygen then binds to this Fe²⁺ heme, forming a ferrous-dioxygen complex. A second electron from CPR reduces this to a ferric-peroxo anion, which undergoes protonation to yield the hydroperoxo intermediate (Compound 0). Subsequent protonation promotes heterolytic O-O bond cleavage, generating the electrophilic ferryl-oxo species (Compound I, or Fe⁴⁺=O). This high-valent iron-oxo complex abstracts a hydrogen atom from the substrate radical, followed by rapid oxygen rebound to hydroxylate the substrate and restore the ferric resting state. A distinctive feature of CYP2E1 is its propensity for uncoupling during the catalytic cycle, where electron transfer proceeds without productive substrate oxidation, leading to the release of reactive oxygen species. With small substrates, cycles can result in superoxide (O₂⁻•) formation from the oxy-ferrous complex or hydrogen peroxide (H₂O₂) from peroxo intermediates, contributing to oxidative stress. This uncoupling is exacerbated by the enzyme's narrow active site and high NADPH oxidase activity. Kinetic parameters for CYP2E1 activity reflect its role in metabolizing low-molecular-weight compounds at physiological concentrations. For ethanol, a prototypical substrate, the Michaelis constant (Kₘ) is approximately 10 mM, indicating operation at high substrate levels, while the maximum velocity (Vₘₐₓ) is significantly influenced by the lipid membrane environment, which affects enzyme oligomerization and electron transfer efficiency.

Substrates and Metabolism

CYP2E1 primarily catalyzes phase I oxidative metabolism of small, hydrophobic molecules, converting them into more polar products that can undergo further conjugation or excretion. This enzyme plays a key role in the bioactivation of both xenobiotics and endogenous compounds, often generating reactive intermediates that contribute to toxicity or physiological regulation. Among xenobiotics, CYP2E1 metabolizes ethanol to acetaldehyde, accounting for approximately 10% of total ethanol oxidation under moderate intake conditions, with the proportion increasing when alcohol dehydrogenase becomes saturated. It also bioactivates acetaminophen to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and leads to hepatotoxicity. Benzene is oxidized by CYP2E1 to benzene oxide, an epoxide intermediate that can form further reactive species implicated in hematotoxicity and leukemogenesis. Recent studies highlight CYP2E1's role in metabolizing the emerging contaminant 1,4-dioxane to β-hydroxyethoxyacetic acid (HEAA), promoting liver oxidative stress, cytotoxicity, and preneoplastic lesions in animal models. Additionally, 2023–2025 research identifies CYP2E1 as a target in neuroinflammation, where its activity exacerbates toxin-induced responses in the central nervous system. For endogenous substrates, CYP2E1 oxidizes acetone to acetol as part of ketone body catabolism, particularly during fasting or diabetes. It performs ω-1 hydroxylation of fatty acids, such as to 11-hydroxylauric acid, influencing lipid homeostasis. A representative probe for CYP2E1 activity is the 6-hydroxylation of , with a reported Km of approximately 0.4 mM in human liver microsomes.

Physiological and Pathological Roles

Xenobiotic and Endogenous Metabolism

CYP2E1 plays a dual role in xenobiotic metabolism, facilitating both detoxification through inactivation and bioactivation that can lead to toxicity. It oxidizes small, hydrophobic xenobiotics into more polar metabolites that are easier to excrete, such as benzene and certain volatile compounds. Conversely, CYP2E1 bioactivates procarcinogens, notably N-nitrosamines like N-nitrosodimethylamine (NDMA), converting them into reactive intermediates that form DNA adducts and contribute to carcinogenesis. This bioactivation is particularly relevant for environmental toxins and tobacco-derived nitrosamines, where CYP2E1's activity can enhance mutagenic potential. For ethanol and acetaminophen, CYP2E1 contributes to their metabolism by producing toxic intermediates (acetaldehyde and NAPQI, respectively), which can lead to oxidative stress and cellular damage despite eventual detoxification pathways. In endogenous metabolism, CYP2E1 supports physiological homeostasis by processing key substrates during metabolic stress. During fasting or starvation, it metabolizes ketone bodies, primarily acetone, into acetol and other intermediates, aiding clearance and preventing ketosis-related toxicity; CYP2E1-null models exhibit over 20-fold elevated acetone levels under these conditions. This process also contributes to gluconeogenesis, as acetol can be further metabolized to products that feed into glucose production pathways. Additionally, CYP2E1 participates in the catabolism of certain endogenous substrates, including minor contributions to testosterone metabolism. Its expression is regulated by sex steroids to help maintain hormonal balance. CYP2E1 interacts with other cytochrome P450 enzymes in substrate metabolism, showing overlap in handling certain xenobiotics like nitrosamines, though it primarily processes smaller molecules distinct from the larger aromatic compounds handled by isoforms such as . The enzyme maintains physiological balance through tightly regulated expression: basal activity is low to avoid unnecessary oxidative burden and futile metabolic cycling, but it is inducible by fasting, ethanol, or xenobiotic exposure via mechanisms like protein stabilization and transcriptional activation, allowing adaptation to increased substrate loads. This inducible nature ensures efficient detoxification and endogenous substrate handling without chronic stress under normal conditions.

Oxidative Stress and Toxicity

CYP2E1 contributes to oxidative stress primarily through the generation of reactive oxygen species (ROS) during its catalytic cycle, particularly when the cycle becomes uncoupled from substrate metabolism. In the uncoupled state, electrons from NADPH are diverted to molecular oxygen, producing superoxide anion (O2∙−O_2^{\bullet-}) and hydrogen peroxide (H2_2O2_2), which can further react to form more reactive species like the hydroxyl radical (⋅\cdotOH). This uncoupling is inherent to CYP2E1 due to its low efficiency in hydroxylating substrates, leading to substantial ROS leakage even under basal conditions. Ethanol induction of exacerbates ROS production, with chronic exposure increasing enzyme levels up to 10-fold, thereby amplifying ROS generation proportionally and intensifying oxidative stress in hepatocytes. 's high NADPH oxidase activity further drives this process, as the enzyme consumes NADPH at an elevated rate without complete oxygen reduction, recycling NADP+^+ and sustaining ROS output, including superoxide, hydrogen peroxide, and hydroxyethyl radicals. This activity positions as a major source of oxidant burden in the liver, distinct from other P450 isoforms. The ROS produced by CYP2E1 initiate lipid peroxidation, a chain reaction that damages polyunsaturated fatty acids in cell membranes, yielding toxic aldehydes such as . acts as a signaling molecule and cytotoxin, forming adducts with proteins and DNA, which propagate oxidative damage and disrupt cellular homeostasis. In hepatocytes, this leads to mitochondrial dysfunction, characterized by impaired electron transport chain activity, reduced ATP production, and release of pro-apoptotic factors, ultimately triggering apoptosis. CYP2E1-mediated oxidative stress synergizes with alcohol dehydrogenase (ADH) in alcohol toxicity, as ADH-generated acetaldehyde enhances activity and ROS output, creating a vicious cycle of oxidant production and cellular injury in the liver. To counteract this, cells mount protective responses, including upregulation of superoxide dismutase (SOD) and catalase, which convert superoxide to hydrogen peroxide and then to water, mitigating ROS accumulation. Additionally, the Nrf2 pathway is activated by CYP2E1-induced oxidants, translocating Nrf2 to the nucleus to induce transcription of antioxidant genes like those encoding SOD, catalase, and heme oxygenase-1, thereby restoring redox balance.

Disease Associations

Liver and Metabolic Diseases

CYP2E1 plays a central role in alcoholic liver disease (ALD) through its induction by chronic ethanol consumption, which elevates enzyme expression 2-3 fold in hepatocytes, enhancing the microsomal ethanol oxidizing system and generating reactive oxygen species (ROS). This induction promotes lipid peroxidation, mitochondrial dysfunction, and inflammation, contributing to hepatic steatosis and progression to fibrosis in both human patients and rodent models. In CYP2E1 knockout mice, ethanol-induced steatosis and fibrosis are markedly reduced, underscoring the enzyme's causative involvement. Furthermore, ethanol induction of CYP2E1 exacerbates acetaminophen hepatotoxicity by increasing production of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), leading to enhanced oxidative stress and hepatocyte necrosis in ALD patients. In nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), CYP2E1 expression is upregulated in the livers of obese and diabetic individuals, correlating with disease severity. This elevation drives lipid peroxidation via excessive ROS production during fatty acid metabolism, fostering oxidative damage, inflammation, and insulin resistance that accelerate steatosis to NASH transition. High-fat diet-fed wild-type mice exhibit significantly higher malondialdehyde levels and NASH histological scores compared to CYP2E1-null counterparts, confirming the enzyme's promotion of lipid peroxidation-mediated injury. Studies of CYP2E1 polymorphisms and insulin resistance in obese patients with NASH have been conducted, with mixed results on genetic susceptibility. CYP2E1 contributes to drug-induced liver injury (DILI) by metabolizing xenobiotics into reactive intermediates that form protein adducts, triggering immune-mediated hepatotoxicity. In halothane hepatitis, CYP2E1 catalyzes the oxidative defluorination of halothane to trifluoroacetyl (TFA) chloride, which covalently binds to hepatic proteins (e.g., 50-100 kDa adducts), eliciting antibody production and idiosyncratic liver damage in susceptible individuals. Adduct formation is concentration- and time-dependent, inhibited by CYP2E1 blockers like 4-methylpyrazole, highlighting the enzyme's specificity in this process. Recent 2024 studies using CYP2E1 knockout mice demonstrate that the enzyme is the primary mediator of 1,4-dioxane (DX) metabolism at high doses, converting it to β-hydroxyethoxyacetic acid while inducing hepatic oxidative stress, GSH depletion, and cytotoxicity; null mice show ~64% reduced DX metabolism and attenuated liver toxicity. CYP2E1 exacerbates metabolic syndrome features, particularly insulin resistance, by generating ROS that impair insulin signaling in hepatocytes, as evidenced by stable CYP2E1 overexpression mimicking palmitate-induced dysregulation and reduced sensitivity in knockout models protected against high-fat diet-induced obesity and glucose intolerance. In gestational diabetes mellitus (GDM), the CYP2E1 C-1054T polymorphism (T allele) increases risk (OR=1.275) via heightened ROS and insulin resistance (elevated HOMA-IR), with combined variants further elevating susceptibility in Chinese women.

Cancer and Other Disorders

CYP2E1 plays a significant role in the bioactivation of tobacco-specific nitrosamines, such as N-nitrosodimethylamine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which are implicated in lung carcinogenesis among smokers. Polymorphisms in the CYP2E1 gene, particularly the RsaI/PstI variant (rs6413432), have been studied in relation to lung cancer risk, with a 2015 meta-analysis indicating the c2 allele as a decreased risk factor among Asians (OR ≈0.78). These variants may influence enzymatic activity, leading to production of reactive metabolites that form DNA adducts in lung epithelial cells. Genetic variations in CYP2E1 also contribute to risks of esophageal and gastric cancers, particularly through interactions with environmental carcinogens. Studies of the RsaI/PstI polymorphism in Asian cohorts have explored susceptibility, though a 2016 meta-analysis found no overall association with gastric cancer risk. For esophageal squamous cell carcinoma, DraI and RsaI variants have been investigated for potential associations with enhanced activation of nitrosamines and other procarcinogens in smokers. These polymorphisms alter CYP2E1 expression, potentially promoting mutagenesis in gastrointestinal tissues. In neurological disorders, elevated CYP2E1 expression exacerbates neuroinflammation and cognitive impairments, as demonstrated in recent rodent models. In lipopolysaccharide-induced neuroinflammation paradigms from 2023–2025 studies, CYP2E1 upregulation in the hippocampus correlates with worsened spatial learning and memory deficits, while CYP2E1 knockout ameliorates these outcomes by reducing oxidative damage and microglial activation. CYP2E1 is also implicated in Parkinson's disease through its metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that models dopaminergic neuron loss; in MPTP-treated mice, CYP2E1 inhibition or knockout paradoxically protects against striatal lesions, suggesting the enzyme's role in generating toxic intermediates like MPP+. Neuronal CYP2E1 activity thus modulates vulnerability to parkinsonism via bioactivation of environmental toxins. Cardiovascular effects of CYP2E1 include contributions to systolic dysfunction in chronic alcoholics, where ethanol-inducible CYP2E1 generates reactive oxygen species that impair myocardial contractility. Inhibition of CYP2E1 in rodent models of chronic alcohol exposure prevents left ventricular systolic dysfunction, restoring ejection fraction and reducing apoptosis in cardiomyocytes. Additionally, benzene exposure, primarily metabolized by CYP2E1 to quinone metabolites, is linked to coronary artery disease risk through endothelial dysfunction and inflammation; occupational studies associate benzene exposure with increased cardiovascular events, with CYP2E1 variants potentially amplifying oxidative stress in vascular tissues. As of 2025, CYP2E1 has been shown to aggravate doxorubicin-induced myocardial injury by disrupting mitochondrial dynamics and promoting apoptosis. A 2024 meta-analysis on antiretroviral drug-induced liver injury primarily implicates CYP2B6 polymorphisms.

Modulators and Applications

Inhibitors and Inducers

CYP2E1 activity is primarily induced by ethanol through stabilization of the enzyme protein, leading to increased expression in the liver and other tissues such as blood lymphocytes and the esophagus. also induces CYP2E1 via similar post-transcriptional stabilization mechanisms, enhancing its role in xenobiotic metabolism. Tobacco smoke, particularly through polycyclic aromatic hydrocarbons (PAHs), induces CYP2E1 activity, contributing to altered drug metabolism in smokers. Several compounds inhibit CYP2E1, categorized by mechanism. Competitive inhibitors include 4-methylpyrazole (fomepizole), which exhibits high selectivity with a Ki of 2.0 μM and plasma concentrations of 17–250 μM. Chlormethiazole acts as a mechanism-based inhibitor with a Ki/IC50 of 1.0 μM and moderate selectivity, impacting as well. Diethyldithiocarbamate (DDC), a metabolite of disulfiram, functions via mechanism-based inactivation with a Ki/IC50 of 5.3–34 μM but shows poor selectivity across multiple CYPs including 1A2, 2A6, 2B6, 2C8, and . Natural compounds also modulate CYP2E1, often as inhibitors. Diallyl sulfide from garlic acts competitively with a Ki/IC50 of 6.3–17.3 μM and potential high selectivity, reducing ethanol-induced liver injury in models. Curcumin, a phytochemical from turmeric, inhibits CYP2E1 activity, contributing to its protective effects against hepatotoxicity and supporting cancer prevention by limiting procarcinogen activation. Recent developments highlight novel synthetic inhibitors targeting in neuroinflammation. The indazole derivative Q11 serves as a potent, selective inhibitor with an IC50 around 1 μM, demonstrating efficacy in rat models of lipopolysaccharide-induced neuroinflammation by reducing oxidative stress and glial activation while maintaining selectivity over other P450 isoforms. These findings position Q11 as a candidate for treating neuroinflammatory conditions associated with upregulation.

Clinical and Therapeutic Implications

CYP2E1 pharmacogenomics plays a key role in personalized medicine, particularly for dosing adjustments in variant carriers. Genetic polymorphisms in , such as the 1D allele, influence acetaminophen oxidation rates, with African-Americans exhibiting slower metabolism compared to European-Americans, potentially requiring tailored dosing to minimize toxicity risk. Similarly, variants like the RsaI c2 allele of CYP2E15B are associated with increased susceptibility to alcoholic liver disease and higher alcohol consumption tendencies, enabling genotyping to predict individual alcohol sensitivity and guide risk assessment. In therapeutics, CYP2E1 inhibitors offer protective strategies against acetaminophen overdose by reducing formation of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). For instance, concurrent CYP2E1 inhibition allows safe escalation of high-dose acetaminophen while mitigating hepatotoxicity, as demonstrated in preclinical models. Fomepizole, a known CYP2E1 inhibitor, has shown potential in human cases of acetaminophen poisoning by blocking NAPQI production, supporting its adjunctive use in overdose management. Broadly, coadministration of cytochrome P450 inhibitors, including those targeting CYP2E1, prevents paracetamol-induced liver damage in animal studies, highlighting their therapeutic utility. While CYP2E1 inducers can enhance prodrug activation for certain xenobiotics, their clinical application remains limited compared to inhibitory approaches. Diagnostic applications leverage CYP2E1 phenotyping for liver function evaluation and exposure monitoring. Chlorzoxazone serves as a validated, non-invasive probe substrate for assessing in vivo CYP2E1 activity through 6-hydroxylation measurement, aiding in the diagnosis of hepatic impairment. Additionally, breath acetaldehyde levels, generated via CYP2E1-mediated ethanol metabolism, act as a biomarker for recent alcohol exposure, with elevated concentrations indicating CYP2E1 involvement in oral cavity and systemic processing. Emerging research from 2023–2025 underscores CYP2E1's expanding therapeutic and environmental roles. In phytoremediation, transgenic plants expressing human CYP2E1, such as petunia and poplar, demonstrate enhanced degradation of volatile pollutants like benzene, toluene, and formaldehyde. For Alzheimer's disease, CYP2E1 inhibition emerges as a target for mitigating neuroinflammation, with novel inhibitors like Q11 reducing oxidative stress and pathology in preclinical models, positioning it as a candidate for neuroprotective therapy. In personalized oncology, CYP2E1 pharmacogenomics informs chemotherapy toxicity prediction; for example, the 7632T>A polymorphism correlates with in cisplatin-treated patients and peripheral neuropathy risk in patients undergoing , enabling genotype-guided dosing adjustments.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7217708/
  2. https://www.sciencedirect.com/topics/neuroscience/cytochrome-p450-2e1
  3. https://www.ncbi.nlm.nih.gov/gene/1571
  4. https://omim.org/entry/124040
  5. https://www.informatics.jax.org/marker/MGI:88607
  6. https://www.uniprot.org/uniprotkb/P05182/entry
  7. https://www.sciencedirect.com/science/article/abs/pii/S0378427404000852
  8. https://www.researchgate.net/figure/Comparison-of-CYP2E1-Allele-Frequencies-Percentage-in-Population-Detected-with-RFLP_tbl3_41563735
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3525247/
  10. https://www.pharmvar.org/htdocs/cyp2e1.htm
  11. https://ehp.niehs.nih.gov/doi/pdf/10.1289/ehp.021101213
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC10234025/
  13. https://pubmed.ncbi.nlm.nih.gov/41148602/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3311288/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC3979157/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5627779/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC8215780/
  18. https://pubmed.ncbi.nlm.nih.gov/7632158/
  19. https://www.sciencedirect.com/science/article/abs/pii/S0168827801002239
  20. https://pubmed.ncbi.nlm.nih.gov/8123198/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC1884181/
  22. https://www.mdpi.com/2039-4713/15/1/20
  23. https://pubmed.ncbi.nlm.nih.gov/14500779/
  24. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1432-1033.1996.0476z.x
  25. https://link.springer.com/article/10.1007/s00210-025-04721-8
  26. https://pubmed.ncbi.nlm.nih.gov/7710685/
  27. https://www.nature.com/articles/cddis201378
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3615729/
  29. https://www.jbc.org/article/S0021-9258%2819%2933186-2/fulltext
  30. https://pubmed.ncbi.nlm.nih.gov/9665827/
  31. https://pubmed.ncbi.nlm.nih.gov/8530344/
  32. https://www.sciencedirect.com/science/article/pii/S0021925817457619
  33. https://onlinelibrary.wiley.com/doi/10.1155/2017/4680732
  34. https://aopwiki.org/aops/260
  35. https://www.uniprot.org/uniprotkb/P05181/entry
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC2586265/
  37. https://www.jbc.org/article/S0021-9258(20)63519-0/fulltext
  38. https://www.rcsb.org/structure/3T3Z
  39. https://pubmed.ncbi.nlm.nih.gov/25533469/
  40. https://doi.org/10.1074/jbc.M805999200
  41. https://doi.org/10.1074/jbc.M707630200
  42. https://pubs.acs.org/doi/10.1021/cr0307143
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2268632/
  44. https://aopwiki.org/relationships/1512
  45. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/microsomal-ethanol-oxidizing-system
  46. https://quizlet.com/652429472/lecture-23-ethanol-metabolism-flash-cards/
  47. https://doi.org/10.1080/03602532.2019.1632889
  48. https://pubmed.ncbi.nlm.nih.gov/16801720/
  49. https://pubmed.ncbi.nlm.nih.gov/10741631/
  50. https://pubmed.ncbi.nlm.nih.gov/9548799/
  51. https://pubmed.ncbi.nlm.nih.gov/20036650/
  52. https://pubmed.ncbi.nlm.nih.gov/9010585/
  53. https://doi.org/10.1007/s00204-024-03811-5
  54. https://pubmed.ncbi.nlm.nih.gov/40122152/
  55. https://pubmed.ncbi.nlm.nih.gov/10424765/
  56. https://pubmed.ncbi.nlm.nih.gov/10553002/
  57. https://pubmed.ncbi.nlm.nih.gov/9354595/
  58. https://pubmed.ncbi.nlm.nih.gov/25815637/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC5259652/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC3199085/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8774478/
  62. https://pubmed.ncbi.nlm.nih.gov/12679052/
  63. https://pubmed.ncbi.nlm.nih.gov/10427467/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC5841237/
  65. https://www.sciencedirect.com/science/article/abs/pii/S014296122200360X
  66. https://www.sciencedirect.com/science/article/pii/S2213231714000998
  67. https://journals.physiology.org/doi/10.1152/ajpgi.00151.2009
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4757513/
  69. https://www.sciencedirect.com/science/article/abs/pii/S0041008X14000805
  70. https://pubmed.ncbi.nlm.nih.gov/20594230/
  71. https://onlinelibrary.wiley.com/doi/full/10.1002/hep.21004
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC9454765/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3445664/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3968292/
  75. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1530-0277.1997.tb04496.x
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC11500436/
  77. https://www.nature.com/articles/srep32229
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC4568918/
  79. https://pubmed.ncbi.nlm.nih.gov/9809991/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC4887804/
  81. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048265
  82. https://pubmed.ncbi.nlm.nih.gov/10574678/
  83. https://www.sciencedirect.com/science/article/abs/pii/S0891584925001820
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC3846836/
  85. https://pubmed.ncbi.nlm.nih.gov/17017526/
  86. https://pubmed.ncbi.nlm.nih.gov/22967841/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC5590846/
  88. https://biosignaling.biomedcentral.com/articles/10.1186/s12964-025-02197-w
  89. https://www.nature.com/articles/s41598-024-79965-0
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC7603454/
  91. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/j.1365-2044.2008.05686.x
  92. https://www.sciencedirect.com/science/article/abs/pii/S0009279714001653
  93. https://pubmed.ncbi.nlm.nih.gov/11346483/
  94. https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301096
  95. https://core.ac.uk/download/pdf/232829629.pdf
  96. https://pubmed.ncbi.nlm.nih.gov/28663312/
  97. https://journals.lww.com/jpharmacogenetics/abstract/1998/08000/the_rsai_polymorphism_of_cyp2e1_and_susceptibility.7.aspx
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC3005010/
  99. https://pubmed.ncbi.nlm.nih.gov/37918853/
  100. https://pubmed.ncbi.nlm.nih.gov/40803359/
  101. https://pubmed.ncbi.nlm.nih.gov/15027815/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC3697796/
  103. https://pubmed.ncbi.nlm.nih.gov/11684359/
  104. https://www.mdpi.com/2072-6694/10/1/20
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC6483939/
  106. https://europepmc.org/article/pmc/pmc2040402
  107. https://pubmed.ncbi.nlm.nih.gov/22188361/
  108. https://journal.waocp.org/article_91874_8a15134f48571adf59f9e29769c8e342.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.